Motofumi Sasaki
Matsue, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A Diagnostic Blind Spot in Pseudo-Bartter Syndrome: Aberrant Renin-angiotensin-aldosterone System Activation from Focal Renal Scarring.
Journal: Internal medicine (Tokyo, Japan)
Published: November 12, 2025
Cystatin C Confirms the Canagliflozin eGFR Slope Benefit in CANPIONE.
Journal: Kidney international reports
Published: October 31, 2025
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
Journal: Kidney international
Published: March 03, 2024
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
Journal: Diabetes, obesity & metabolism
Published: January 21, 2022
Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Journal: Diabetes research and clinical practice
Published: September 23, 2016
Long-term Efficacy and Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes Mellitus.
Journal: Internal medicine (Tokyo, Japan)
Published: May 17, 2016
The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO).
Journal: Diabetes & vascular disease research
Published: May 08, 2012
Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin.
Journal: Diabetes
Published: February 24, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026